Brief: Syndax Announces Positive Data For Revumenib In Patients With Acute Leukemias From BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

Syndax Pharmaceuticals

11/12/2023 12:42

Dec 11 (Reuters) - Syndax Pharmaceuticals Inc  SNDX.O :
    * SYNDAX ANNOUNCES POSITIVE DATA FOR REVUMENIB IN PATIENTS
WITH
ACUTE LEUKEMIAS FROM THE BEAT AML, SAVE AML AND AUGMENT-102
PHASE 1 COMBINATION TRIALS
    * SYNDAX PHARMACEUTICALS INC: REVUMENIB WAS WELL TOLERATED
WITH NO
NEW SAFETY SIGNALS IDENTIFIED
    * SYNDAX: 100% CRC OBSERVED IN BEAT AML TRIAL EXPLORING
REVUMENIB
IN COMBINATION WITH VENETOCLAX/AZACITIDINE IN NEWLY DIAGNOSED
MNPM1 OR KMT2AR AML
    * SYNDAX PHARMACEUTICALS INC: 78% CRC OBSERVED IN SAVE AML
TRIAL
    * SYNDAX PHARMACEUTICALS INC: 33% CRC OBSERVED IN
AUGMENT-102
TRIAL

Source text for Eikon:  ID:nPn31nmG6a 
Further company coverage:  SNDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))